Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers

NCT00425178 is registered in ClinicalTrials.gov with Venturis Therapeutics, Inc. as lead sponsor.

NCT NCT00425178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00425178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Patients With Diabetic or Venous Stasis Ulcers
Lead sponsor
Venturis Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 2, 2005
Completion date
December 1, 2006
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic wounds, diabetes, venous stasis ulcers